IMUXImmunic, Inc.
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development …
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Can Immunic (IMUX) Climb 163.03% to Reach the Level Wall Street Analysts Expect? The mean of analysts' price targets for Immunic (IMUX) points to a 163% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. | ||
 Immunic advances MS drug toward key Phase 3 data, expects results by year-end Immunic Inc (NASDAQ:IMUX, FRA:10VA) is preparing for a series of clinical and corporate milestones as it advances its lead drug candidate vidofludimus calcium through late-stage development in multiple sclerosis, while expanding its leadership team ahead of potential regulatory filings and... | ||
 Immunic appoints Elena Ridloff to board of directors Immunic Inc (NASDAQ:IMUX, FRA:10VA) has named Elena Ridloff to its board of directors, the biotechnology company said Monday. Ridloff currently serves as CFO at Sionna Therapeutics. She previously held the same role at ACADIA Pharmaceuticals, where she helped raise $600 million in capital and... | ||
 Immunic CEO on Q2 progress and Phase 3 MS trial milestones Immunic Inc (NASDAQ:IMUX, FRA:10VA) CEO Erik Lundgren spoke with Proactive's Stephen Gunnion about the company's second-quarter results, its leadership transition and the milestones set to shape the next phase of its multiple sclerosis (MS) programme. Lundgren explained why he joined Immunic, pointing to the potential of lead candidate vidofludimus calcium and the chance to lead the business into two pivotal Phase 3 readouts. Both the ENSURE-1 and ENSURE-2 Phase 3 studies in relapsing MS are fully enrolled and on track to report results by year-end, with the company already engaging health authorities ahead of the data and any subsequent regulatory filing. The interview also covered Immunic's strengthened leadership team, including new chairman Michael Bonney, board member Jon Congleton and chief medical officer Dr Michael A. Panzara - part of a push to build deep MS expertise to support the company's long-term strategy. Lundgren flagged another key goal: launching a Phase 3 study in progressive MS before year-end. "The other big milestone we're really focused on is initiating a Progressive MS study by the end of this year," he said, adding that the programme could widen the market opportunity for vidofludimus calcium and address a significant area of unmet need. On financials, Immunic ended Q2 with around $155 million in cash, providing runway into late next year, with further funding potentially available through conversion of pre-funded warrants following positive clinical data. For more interviews with leading healthcare and biotechnology companies, visit the Proactive YouTube channel. Don't forget to like this video, subscribe to the channel and enable notifications so you never miss future content. Read Proactive's Editorial Policy here: https://www.proactiveinvestors.co.uk/pages/editorialPolicy #Immunic #MultipleSclerosis #MS #Biotech #Biotechnology #ClinicalTrials #Phase3 #VidofludimusCalcium #Healthcare #DrugDevelopment #Nasdaq #Investing #Biopharma #ProactiveInvestors | PProactive | |